Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have previously received a treatment called Equecabtagene Autoleucel Injection
- People who took part in an earlier clinical study or real-world study related to this treatment must have fully completed or officially withdrawn from that study before joining
- People who are willing to sign a consent form that has been reviewed and approved by an ethics committee
Who may not be able to join:
- People who received any other cell or gene therapy based on a lentiviral vector (whether an approved product or an experimental one in a clinical trial) at any point between receiving the Equecabtagene Autoleucel Injection and signing the consent form for this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jian Li, PhD, Peking Union Medical College Hospital
Phone: +86 025-58287610
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the safety profile of Equecabtagene Autoleucel Injection in treated patients.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.